INTRODUCTION
To determine the extent of APA-mediated 3'-UTR shortening and lengthening in PDA, we 156 compared the PDUI scores for each gene between the tumor and normal samples (Fig. 1A,B ). genes found to have significantly shortened 3'-UTR lengths were many known PDA growth-164 promoting genes, including PAF1 (Polymerase Associated Factor 1), FLNA (Filamin-A), ENO1 165 (α Enolase), RALGDS (Ral guanine nucleotide dissociation stimulator), TRIP10 (Thyroid 166 Hormone Receptor Interactor 10) and ALDOA (Aldolase A). ALDOA and PAF1 have recently 167 been described as oncogenes in PDA 50-53 , while ENO1, RALGDS, TRIP10 and FLNA are 168 known to mediate pancreatic cancer cell proliferation, survival and migration [54] [55] [56] [57] [58] [59] . We did not 169 detect 3'-UTR alterations in recurrently mutated PDA genes, reflecting the predominant role of 170 APA in regulating gene expression rather than gene function. We visualized the 3'-UTR profiles 171 of these genes between TCGA and GTEx samples to confirm 3'-UTR shortening (see FLNA,
172
PAF1 as examples, Fig. 1D ).
174
PDA samples are often characterized by substantial stromal contamination 5 ; therefore, we 175 sought to determine if significant APA events were present in the stroma or the tumor 176 epithelium. First, we analyzed PDUI changes in a subset of 69 high purity TCGA-PAAD tumor 177 samples 4 (>33% tumor content). 89% of gene hits from our original analysis showed up as 178 significant hits in the high purity dataset, suggesting that the majority of the detected APA 179 changes were not attributable to stromal contamination (Supp. Fig. 2A,B ). We further addressed 180 this concern by visualizing the 3'-UTR profile of our candidate genes in an independent dataset 181 containing RNA-seq information from 65 matched human PDA samples with micro-dissected 182 tumor epithelia and stroma 5, 60 . As an example, Fig. 1E shows the differential 3'-UTR shortening 183 of FLNA and PAF1 in patient tumor epithelium (tumor cells) as compared to the matched 184 stroma.
186
We validated the presence of alternative 3'-UTR forms for several APA-regulated candidate Next, we asked whether APA events added additional prognostic information to PDA patient 232 outcomes above the usual demographic and clinical factors: age, race, sex, stage, grade and 233 surgical outcome. We selected genes with significant 3'-UTR alterations and univariate 234 prognostic value, defining prognostic classes based on multivariate clustering (Fig. 3A) . This 235 segregated patients into three cohorts based on their 3'-UTR patterns (long=blue; short=red).
236
Cohort A was predominantly associated with proximal PAS usage of genes from Groups 2 and 237 3, while cohort C was associated with distal PAS usage of the same genes. For Group 1 genes, 238 distal PAS usage was predominant in cohort A while proximal PAS usage was predominant in 239 cohort C. Neither patient cohort correlated with any of the known PDA tumor subtypes.
240
Importantly, cohorts A and C displayed significant differences in overall survival, with patients in 241 cohort C living significantly longer than those in cohort A (p=0.02) ( Fig. 3B ). Therefore, patterns 242 of APA can be used as an independent prognostic indicator in PDA.
244
Heterogeneity of proximal PAS usage of metabolic genes in PDA patients.
245
Processes generating genetic and epigenetic heterogeneity can drive tumor evolution 67-69 . We 246 hypothesized that APA could represent such a process, creating a diverse set of 3'-UTR forms 247 and allowing cancer cells to select for those that promote their survival and propagation. To 248 examine this heterogeneity, we compared the extent of proximal PAS usage across patients in 249 any given gene between tumor and normal samples. ALDOA is shown as an example gene that 250 exhibited a tight distribution of proximal PAS usage across normal as well as patient tumors 251 ( Fig. 4A ). The left shift of the tumor sample mean score represents the expected shortening of 252 the ALDOA 3'-UTR. However, for FLNA, while the normal samples had a tight distribution, PDA 253 patients showed greater heterogeneity in proximal PAS usage ( Fig. 4B ). An analysis of 254 heterogeneity in proximal PAS usage for all genes revealed that while the majority of genes did 255 not show a significant change between normal and tumor conditions, 68 genes showed greater 256 heterogeneity in tumor (orange) samples and only 9 genes showed greater heterogeneity in 257 normal (purple) samples (Fig. 4C ). This heterogeneity was not due to intrinsic differences 258 between the TCGA and GTEx datasets because none of the 215 housekeeping genes in the 259 dataset showed heterogeneity in the extent of proximal PAS usage 70,71 . The subset of 68 genes 260 was enriched in metabolic genes, specifically amino acid transporters and purine metabolism. A 
265
To determine whether the identified APA events drive altered gene expression in PDA, we computed differential gene expression between normal (GTEx) and tumor (TCGA-PAAD) preferentially associated with increased gene expression is consistent with pan-cancer APA 271 analyses and conforms to the expectation that 3'-UTR shortened genes can escape miRNA 272 regulation leading to increased gene expression 30, 72, 73 . In contrast, 3'-UTR lengthened genes 273 showed a similar number of significantly upregulated (n=42) and significantly downregulated 274 (n=41) genes, consistent with pan-cancer analyses, and most likely reflective of positive and 275 negative regulation by RNA-binding proteins 29, 74, 75 .
277
To experimentally validate the relationship between APA and protein expression, we performed 278 luciferase reporter assays in MiaPaCa2 cells, comparing protein expression driven by short and 279 long 3'-UTRs ( Fig. 5C ). We focused on the candidate oncogenes and tumor suppressors 280 validated by 3'-RACE and that showed significant association between 3'-UTR changes and 281 gene expression in tumors. These candidates included ALDOA, FLNA, PAF1, TRIP10, ENO1, 282 SAT1 (shortened and upregulated in tumors) and PPP2R2D (lengthened and downregulated in 283 tumors). We also included RALGDS which is shortened but does not show altered expression in 284 tumors. We cloned the short and long 3'-UTRs of each gene (estimated via 3'-RACE) 285 downstream of a Renilla luciferase reporter and measured luminescence as a readout of protein 286 expression ( Fig. 5C ). To ensure that the long 3'-UTR form for each reporter gene remained 287 intact (i.e., did not undergo APA-mediated shortening upon transfection into cells), we mutated 288 their functional proximal PAS. For all genes tested except ENO1 and RALGDS, the short 3'-289 UTR form showed significantly increased luminescence compared to the long 3'-UTR form ( Fig. 
290
5D). As predicted, the 3'-UTR short and long forms of RALGDS showed similar expression. In 291 contrast to our expectations, the short form of ENO1 showed decreased protein expression 292 suggesting that 3'-UTR shortening is not the sole mechanism regulating protein abundance of 293 ENO1 in PDA. These results also reinforce the observation that shorter 3'-UTRs do not always 294 increase protein expression 30 . Overall, the above results suggest that APA-mediated 3'-UTR 295 alterations can regulate the protein expression of growth-promoting genes in PDA cells. that ALDOA undergoes 3'-UTR shortening and upregulation, we searched the ALDOA 3'-UTR 300 for putative miRNA binding sites that would be lost upon PDA-associated shortening ( Fig. 5E ).
301
We identified the tumor suppressive miRNA miR-122a within this lost region; miR-122a is highly 302 expressed in PDA cell lines 76, 77 . Mutation of the miR-122a site within the long 3'-UTR of ALDOA 303 significantly restored protein expression ( Fig. 5F ). Therefore, altered APA can regulate 304 oncogene expression in PDA through modulation of available regulatory miRNA binding sites.
306
APA-mediated loss of tumor suppressive miRNA binding sites is associated with poor 307 patient outcome.
308
To assess global patterns of APA-mediated miRNA binding site loss we searched for highly 309 conserved miRNA binding sites (conserved across human, mouse, rat, dog and chicken) within 310 the lost 3'-UTRs of all shortened genes. This analysis revealed that 42% of genes lost at least 311 one highly conserved miRNA binding site ( Fig. 6A ), suggesting that alteration of the miRNA 312 binding site repertoire is an important mode of APA-mediated regulation. Next, we sought to 313 determine if any miRNA families were preferentially lost in shortened 3'-UTRs of PDA patients.
314
We computed an index for repression for each miRNA family as a function of the miRNA site 315 context scores (obtained from TargetScan) and the abundance of the 3'-UTR form containing 316 that site. This index was then compared between PDA patients and normal controls to yield a Z-317 score. A lower Z-score for a miRNA family reflects preferential loss of its binding sites due to 3'-318 UTR shortening. Interestingly, 6 of the top 8 identified miRNAs have been implicated as tumor 319 suppressors in PDA, including miR-329 and miR-133a 78-82 ( Fig. 6B ). These results suggest that 320 APA regulates oncogenic gene expression through preferential loss of tumor suppressive 321 miRNA binding sites and may therefore confer a selective advantage to the cell.
323
Next, we determined whether loss of specific miRNA sites associated with 3'-UTR alterations is 324 associated with patient outcome. We quantified loss of highly conserved miRNA binding sites 325 for each patient as a function of the extent of proximal PAS usage in all genes that lost those 326 miRNA sites (see Methods). Clustering in the miRNA feature space revealed 3 patient groups 327 ( Fig. 6C ) with significant differences in overall survival (p=0.012 between Clusters 1 and 3; Fig. 
328
6D). The miRNAs most significantly associated with the patient clusters included miR-133a, 329 miR-124, miR-421, miR-143 and miR-505. Binding sites for each miRNA were preferentially lost 330 from Cluster 1 as compared with Cluster 3, suggesting that loss of these regulatory sites 331 correlates with poor survival of PDA patients (Fig. 6E ). Indeed, miR-133a, miR-124 and miR-tumor suppressive miRNA binding sites 80,83-89 .
335
The APA-regulated gene CSNK1A1 is required for proliferation and clonogenic growth of 336 PDA cells.
337
Our data showed APA-mediated regulatory changes in genes known to promote PDA 338 pathogenesis. We hypothesized that our altered gene list may also contain growth-promoting 339 genes not previously implicated in PDA biology, and therefore new therapeutic targets. We 340 focused on the subset of druggable genes that were significantly shortened and upregulated in 341 PDA. Finally, we overlaid this list with results from a genome-wide CRISPR screen, identifying 342 genes essential for PDA cell proliferation 90 . This analysis identified CSNK1A1, the gene 343 encoding the serine/threonine kinase casein kinase 1α (CK1α). CK1α regulates the Wnt/β-344 catenin signaling pathway and has dual functions in cell cycle progression and cell division 91-93 .
345
CK1α is known to influence tumor progression; however, its role as a tumor suppressor or 346 oncogene is tumor type-dependent 91,93-95 and CK1α has no known roles in PDA. CSNK1A1 has 347 very low gene expression in normal pancreas but is overexpressed in PDA 96 . We found that 348 CSNK1A1 shows significantly higher expression in the PDA epithelium as compared to 349 precursor lesions (premalignant pancreatic intraepithelial neoplasia (PanIN) ( Fig. 7A ) and 350 intraductal papillary mucinous neoplasia (IPMN)). We found no significant difference in 351 CSNK1A1 expression in the stroma between PDA and precursor lesions. We then determined 352 whether differential CK1α activity mediates progression from precursor lesions to PDA. As a first and PDA, it indicates differential CK1α activity between the two conditions. Indeed, the positive 362 targets of CK1α were more highly expressed in PDA epithelium, whereas the negative targets showed increased expression in precursor lesions, indicating that CK1α activity may promote was not present in the stroma between PDA and precursor samples suggesting the specific role 366 of CK1α in PDA epithelium. As predicted by our computational analysis, 3'-RACE showed that 367 CSNK1A1 has an increased proportion of the short 3'-UTR form as compared to the long 3'-368 UTR form in PDA cells (Supp. Fig. 3A ).
370
We then investigated the potential for CK1α inhibition to regulate PDA biology with the widely 371 used small molecule inhibitor D4476 94,96,100 . We treated the PDA cell lines MiaPaCa2 and Suit2 372 with D4476; while MiaPaCa2 and Suit2 cells were both sensitive to D4476 treatment, Suit2 cells 373 displayed a 10-fold lower IC50 (Fig. 7C ). Both cell lines also showed dose-dependent 374 decreases in cell proliferation (Fig. 7D, Supp. Fig. 3B ) and clonogenic growth in the presence of 375 the inhibitor (Fig. 7E,F, Supp. Fig. 3C ). To provide genetic evidence for the role of CK1α in PDA 376 cell growth, we knocked down CSNK1A1 in Suit2 and MiaPaCa2 cells with 3 short hairpin RNAs 377 (shRNA) (Fig. 7G, Supp. Fig. 3D ). In concordance with the pharmacological results, CSNK1A1 
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The PAS mutant expression is normalized to 1. 
855
where A g,m is an indicator function that the short versus long 3'-UTR of the gene g contains the 926 binding site for miRNA m, the impact to the i th person is X m,i . We used Sure Independence 927 Screening (SIS) to search through all affected miRNAs and identify features that were the RNA pellet was washed with 75% ethanol. The pellet was dissolved in RNase-free water 992 and the quality of RNA was assessed using a NanoDrop spectrophotometer. 
